Latest Allarity Therapeutics News & Updates
See the latest news and media coverage for Allarity Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage precision medicine company for oncology
allarity.com- Headquarters
- Tarpon Springs, United States
- Founded year
- 2012
- Company type
- Public company
- Number of employees
- 10–50
Last updated
Latest news about Allarity Therapeutics
In short: Allarity Therapeutics advanced its stenoparib oncology pipeline through Phase 3 manufacturing, key patent approvals, and secured $20 million in funding.
Company announcements
-
Allarity Therapeutics advances stenoparib manufacturing for Phase 3
The campaign is on track for Q3 2026 completion, supporting pivotal ovarian cancer trials and FDA approval. All payments are completed with no further cash needed.
-
Allarity Therapeutics secures US notice of patent allowance
The USPTO issued a Notice of Allowance for the stenoparib DRP® test; patent is expected to grant within three months, potentially providing exclusivity into at least 2039.
-
Allarity Therapeutics presents two AACR 2026 posters on stenoparib
Posters highlight stenoparib's potential in colorectal cancer via WNT modulation and DRP® linking to improved ovarian cancer survival. Posters available on website.
-
Allarity Therapeutics reports 2025 financial results
Cash position stands at $14.7M with runway to mid-2028. Stenoparib gains FDA Fast Track for ovarian cancer and launches VA-funded lung cancer study. Net loss improves to $11.2M.
Media coverage
-
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced...
-
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
Patent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide exclusivity at least into 2039 for stenoparib when used...
-
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Li…
New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® ...
-
Allarity Therapeutics (NASDAQ:ALLR) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - Daily Political
Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.21) earnings per share for the quarter, topping...
Track Allarity Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Allarity Therapeutics competitors & trending companies
Browse news for competitors to Allarity Therapeutics and other trending companies.
Sprint Bioscience
Novakand Pharma
Vivesto
Andon Labs
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global